Life Recovery Systems

What Life Recovery Systems does

Life Recovery Systems (legal entity: Life Recovery Systems HD, LLC) is a privately held US medical device company founded in 2003 and headquartered in Alexandria, Louisiana, with research, development, and manufacturing operations in Kinnelon, New Jersey (the Sid Wolvek Research Center). The company develops and commercializes the ThermoSuit System (TSS), a rapid non-invasive patient-cooling device that uses direct liquid contact and convective heat transfer — a thin film of ice water circulating in a controlled suit — to reduce core body temperature to approximately 33°C in roughly 30 minutes (median 37 minutes in a multi-center clinical evaluation; 27 minutes in Propofol-sedated patients). The system pairs reusable capital hardware with single-use ThermoSuit Disposables Kits (which include an esophageal temperature probe for fast-responding core temperature monitoring) and is currently FDA-cleared for general temperature reduction in hyperthermic patients.

The company's revenue model is direct hospital sales of the capital equipment combined with recurring disposables revenue per patient cooling event, supplemented by reimbursement guidance, on-site training, and a Quick Start Guide. Named customers are concentrated in Louisiana and New Jersey and include Rapides Regional Medical Center, Virtua Health, and CHRISTUS St. Frances Cabrini Hospital, where the device is used in emergency departments, cardiac cath labs, and cardiovascular/oncology programs. The company actively encourages hospital customers to position themselves as Heatstroke Treatment Centers of Excellence and engage local EMS providers as referral partners.

Beyond the FDA-cleared hyperthermia indication, Life Recovery Systems is pursuing expansion into post-cardiac-arrest therapeutic hypothermia and — most significantly — acute ischemic stroke, where it received FDA Investigational Device Exemption approval (reported March 2026) to run a pivotal trial enrolling up to 160 patients at up to 8 US hospitals, with post-stroke cognitive impairment as the primary endpoint. This stroke program follows the SISCO pilot study, whose peer-reviewed publication in Frontiers of Neurology (November 7, 2025) supported feasibility, safety, and rapid cooling in ischemic stroke patients under the prior IDE. Leadership comprises CEO Matt Center, co-founder/VP R&D Dr. Robert B. Schock, co-founder/CMO/Chairman Dr. Robert J. Freedman, and CFO Coan I. Knight; the original product was developed with non-dilutive funding from the NIH National Heart, Lung, and Blood Institute.

Name

Life Recovery Systems

Legal name

Life Recovery Systems HD, LLC

Website

https://life-recovery.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Life Recovery Systems is a US private medical device company (founded 2003, Alexandria, LA) that develops and sells the ThermoSuit System — a rapid non-invasive patient-cooling device using iced-water immersion — to hospital emergency departments and cardiac programs for therapeutic hypothermia and hyperthermia, with an active FDA IDE pivotal trial targeting ischemic stroke.

Ownership category

akta.pro rank

Product category

Therapeutic Hypothermia Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Continuous Temperature & Fever Monitoring (Wearable Thermometry) (HLAHACAK)

Keywords

• Therapeutic hypothermia devices
• Rapid patient cooling
• Emergency medical equipment
• Targeted temperature management
• Cardiac arrest cooling

Headquarters

HQ city

Alexandria

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Capital Equipment & Disposable Sales of the ThermoSuit System: Life Recovery Systems sells the ThermoSuit System to hospitals. The system includes reusable hardware (ice water pump and control unit, suit components) and disposable ThermoSuit Disposables Kits (which include the esophageal temperature probe). The sales model is hospital capital purchase combined with recurring disposable revenues per patient cooling event.
2. Reimbursement-Supported Hospital Sales: The company supports customers with a Reimbursement section on its website, indicating that coding and reimbursement guidance is part of the commercial offering, enabling hospitals to bill third-party payers for therapeutic hypothermia / cooling procedures performed with the ThermoSuit.

Go-to-market motion1 record

Distribution channels2 records

Core offering

Life Recovery Systems develops and manufactures the ThermoSuit System (TSS), a rapid non-invasive patient cooling medical device that uses direct liquid contact (a thin film of iced water) and convective heat transfer to reduce core body temperature, typically cooling patients to a target of 33°C in about 30 minutes. The offering combines reusable capital equipment (ice water pump, control unit, suit) with recurring single-use ThermoSuit Disposables Kits (including an esophageal temperature probe), and is supported by hospital training programs and reimbursement guidance for emergency departments and therapeutic hypothermia programs.

Product overview

Life Recovery Systems offers a single core medical device product — the ThermoSuit System (TSS) — supported by its consumable ThermoSuit Disposables Kit and a ThermoSuit Training Program. The TSS is a rapid non-invasive patient cooling device for therapeutic hypothermia and hyperthermia, used in emergency and operating room settings as a replacement for cooling blankets and gel pads. Founded in 2003 with funding from NIH NHLBI, LRS's product portfolio is unified around the ThermoSuit platform, with clinical research extensions into ischemic stroke and cardiac arrest indications.

Differentiator

Problem solved

Functional benefit

Brands

• ThermoSuit: ThermoSuit is the registered product brand name for LRS's rapid patient cooling / therapeutic hypothermia system that uses iced water immersion (liquid convection) technology. It is described as the Fastest Non-invasive Cooling in the World of Medicine and is FDA-cleared for general temperature reduction in hyperthermic patients.
• ThermoSuit System (TSS)

Products and services

• ThermoSuit System (TSS) Rapid non-invasive patient cooling medical device using direct liquid contact (thin film of iced water) and convective heat transfer to reduce core body temperature, typically cooling patients to a target of 33°C in about 30 minutes. FDA-cleared for general temperature reduction in hyperthermic patients and under FDA IDE investigation for ischemic stroke; sold to hospital emergency departments, cardiac arrest therapeutic hypothermia programs, and critical care units as a replacement for cooling blankets and gel pads.
• ThermoSuit Disposables Kit Single-use consumable kit for the ThermoSuit System that includes the patient suit components and an esophageal temperature probe used for fast-responding core temperature measurement during high-speed cooling induction; sold per patient cooling event to hospital customers.
• ThermoSuit Training Program Hospital training program and materials (Quick Start Guide, Training Mode on the device) delivered to clinical customers to ensure successful operation of the ThermoSuit System in emergency and critical care settings.

Quantifiable outcome

• Median cooling time of 37 minutes (27 minutes in Propofol-sedated patients) to target 33°C — described as the "Fastest Non-invasive Cooling in the World of Medicine"
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• University of Rhode IslandcoreStrategic or Co-development PartnerLRS-sponsored animal studies at the University of Rhode Island (along with the University of Vienna) examined conditions of wet defibrillation in the ThermoSuit. Pigs were subjected to induced VF and defibrillated in the ThermoSuit under randomized test conditions (dry/wet, normothermic/hypothermic). The studies demonstrated that defibrillation can be successful in wet conditions assuming adhesive electrodes are applied to dry skin before activating coolant flow.
• University of ViennacoreStrategic or Co-development PartnerLRS-sponsored animal studies at the University of Vienna (along with the University of Rhode Island) investigated wet defibrillation in the ThermoSuit. The resulting research was published in the American Journal of Emergency Medicine (Shraetter A., Weihs W., Holzer M., Janata A., Behringer W., Losert U., Ohley W., Schock R., Sterz F., "External cardiac defibrillation during wet surface cooling in pigs," Am J Emerg Med 2007, 25, 420-424).
• US Food and Drug Administration (FDA)coreOthersThe FDA granted an Investigational Device Exemption (IDE) to LRS to conduct a pivotal clinical trial of the ThermoSuit System in ischemic stroke patients, with enrollment of up to 160 patients at up to 8 hospitals. Previously (June 1, 2023), the FDA met with LRS to review SISCO pilot results and recommended ending the SISCO study and proceeding to a prospective randomized trial. The FDA-cleared current indication is general temperature reduction in hyperthermic patients.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• BD (Becton, Dickinson and Company): BD acquired Medivance and markets the Arctic Sun system for targeted temperature management / therapeutic hypothermia in post-cardiac-arrest and other indications. Arctic Sun is the most established non-invasive surface-cooling competitor to LRS's ThermoSuit in US hospitals.
• ZOLL Medical (Asahi Kasei): ZOLL's Thermogard XP intravascular and surface cooling platform is a leading targeted temperature management system used by hospitals for post-cardiac-arrest care. ZOLL competes directly with ThermoSuit on cooling speed, evidence base, and installed base in US emergency and critical-care settings.
• Attune Medical: Attune Medical markets the ensoETM esophageal cooling device, a non-invasive cooling technology placed in the esophagus to manage patient temperature in the ICU and perioperative settings. It is a directly comparable non-invasive patient cooling modality competing for the same therapeutic hypothermia and targeted temperature management budgets as ThermoSuit.

Emerging players

• BrainCool AB: BrainCool develops the RhinoChill intranasal cooling system and the BrainCool System for targeted temperature management in stroke, cardiac arrest, and oncology. Like LRS, it is focused on rapid non-invasive cooling for neurological indications and competes for similar clinical trial evidence and regulatory positioning.
• EMCOOLS Medical Systems: EMCOOLS develops the EMCOOLS Flex.Pad and HypoCarbon surface cooling pads for rapid non-invasive patient cooling, including post-cardiac-arrest TTM. It is an emerging non-invasive cooling competitor with comparable clinical positioning to LRS in the European and US therapeutic hypothermia markets.

Broad incumbents

• Gentherm: Gentherm is a large medical and automotive thermal management company whose patient temperature management portfolio (warming and cooling blankets, forced-air systems) overlaps with ThermoSuit's hospital use cases. It serves the same hospital procurement channels but with a much broader thermal product portfolio.
• Stryker: Stryker's Medical division supplies patient warming and cooling equipment used in operating rooms and ICUs alongside its broader medtech portfolio. While not a single-product competitor to ThermoSuit, Stryker competes at the hospital capital-equipment purchasing level for thermal management budgets.
• Medtronic: Medtronic's Patient Monitoring business includes temperature management products used in perioperative and critical care settings, and the company has the clinical evidence infrastructure and global sales reach to enter or expand in therapeutic hypothermia. It competes at the level of large hospital systems and integrated delivery networks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ThermosuitLRS
• LinkedInlinkedin.com/company/life-recovery-systems

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Life Recovery Systems